Biotech Co.* | Pharma Co. | Product | Disclosed | Terms/Details |
(Symbol) | (Country) | Funding | (Date) | |
($M) | ||||
Antares | Pharmacia | Undisclosed product | ND | Antares granted Pharmacia exclusive sales and marketing rights for the product in certain European territories; the product will use Antares' transdermal gel technology delivery system (5/1) |
Cephalon | Armstrong Laboratories | Modafinil | ND | Agreement gives Armstrong and Sintong territorial rights to market and distribute modafinil, which Cephalon markets in the U.S. as Provigil (5/24) |
Cephalon | Orphan | Actiq | ND | Cephalon granted Australian and New Zealand sales, marketing and distribution rights for Actiq to Orphan Australia (6/12) |
Cephalon | Ricercas | Angiogenesis inhibitor to treat solid tumors | ND | Ricerca will produce kilogram quantities of the active pharmaceutical ingredient for use in Phase I studies (3/30) |
Cepheid | BioSynTech | Smart Cycler system | ND | BioSynTech will market the system, accessories and consumables in the life science research markets in Malaysia and Singapore (6/14) |
Chiron Corp. | F. Hoffmann- | HIV-1 and hepatitis C virus intellectual property | ND | Roche gains a license to manufacture and sell probe-based HIV-1 and HCV blood screening tests worldwide (5/23) |
Compugen | Sigma- | OligoLibraries | ND | Compugen will provide the content and designs of the OligoLibraries, which will provide access to oligonucleotide collections representing genomes of various organisms for high-throughput analysis of gene function; Sigma-Genosys will manufacture the products (6/26) |
Dendreon | Covance | Provenge | ND | Covance will produce antigen to prepare Provenge for the market (4/5) |
Dragon | Transworld Pharmaceuticals | Formulation of erythropoietin | ND | Agreement giving Dragon sole worldwide manufacturing rights and exclusive marketing rights in Asia to a novel, slow-release formulation of erythropoietin; Transworld will have exclusive marketing rights outside Asia (6/19) |
Dyax Corp. | Wyeth-Genetics | Chemically | ND | Commercial license for the ligand, which has a high capacity and specificity for purification of Wyeth-Genetics' Factor VIII product, ReFacto (5/22) |
Nexell | Baxter | Cell-processing products, including Isolex 300i Magnetic Cell Selection System | ND | Nexell signed a letter of intent to transfer exclusive worldwide rights for sales, marketing and distribution of its cell-processing products to Baxter (6/12) |
Proteome | Sigma-Aldrich | ProteoPrep and other products | ND | The products include ProteoPrep, a line of sample preparation kits; agreement grants Sigma-Aldrich manufacturing and distribution rights to products developed in the collaboration (5/7) |
StemCell | Applied | RosetteSep tumor enrichment products and technology | ND | StemCell will supply RosetteSep tumor enrichment products and technology and Applied Imaging will market and sell the products (5/3) |
The Medicines | Grupo Ferrer | Angiomax | ND | Collaboration for the registration, distribution and promotion of Angiomax in Spain, Portugal, Greece and 18 Latin American markets (6/5) |
The Medicines | Medison | Angiomax | ND | Exclusive marketing and distribution agreement for the registration, distribution and promotion of Angiomax in Israel (5/21) |
NOTES | ||||
# The information in the chart does not cover agreements between biotech companies or agricultural agreements. The chart may include collaborations that occurred prior to April 26, but were not listed in the previous chart. | ||||
* Private companies are indicated with an asterisk; unless otherwise noted, stock symbols listed are on the NASDAQ market. | ||||
** Denotes the date the item ran in BioWorld International. | ||||
ND = Not disclosed, reported and/or available | ||||
AMEX = American Stock Exchange; ASX = Australian Stock Exchange; CSE = Copenhagen Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over The Counter Bulletin Board; TSE = Toronto Stock Exchang; VSE = Vancouver Stock Exchange. | ||||
